🇺🇸 rosiglitazone-metformin in United States
38 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 38
Most-reported reactions
- Cardiac Arrest — 6 reports (15.79%)
- Heat Stroke — 6 reports (15.79%)
- Myocardial Infarction — 4 reports (10.53%)
- Unresponsive To Stimuli — 4 reports (10.53%)
- Bundle Branch Block Right — 3 reports (7.89%)
- Dyspnoea — 3 reports (7.89%)
- Hyperthermia — 3 reports (7.89%)
- Metabolic Acidosis — 3 reports (7.89%)
- Renal Failure Acute — 3 reports (7.89%)
- Supraventricular Tachycardia — 3 reports (7.89%)
Other Diabetes approved in United States
Frequently asked questions
Is rosiglitazone-metformin approved in United States?
rosiglitazone-metformin does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for rosiglitazone-metformin in United States?
GlaxoSmithKline is the originator. The local marketing authorisation holder may differ — check the official source linked above.